Consequently, when designing therapeutic strategies targeting SIRPα-overexpressing cancers, it is critical to consider not only the immunostimulatory effects of SIRPα inhibition on myeloid cell-mediated immunity within the tumor microenvironment but also its direct impact on tumor cells and whether such effects may counteract potential immunotherapeutic benefits. This evidence concerns the gene SIRPA and neoplasm.